Drug Interactions between deuruxolitinib and sirolimus

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration of deuruxolitinib with other Janus Kinase (JAK) inhibitors, biologic immunomodulators, or other potent immunosuppressants (e.g., cyclosporine) may potentiate the risk of infections, major adverse cardiovascular events (MACE), and other malignancies, including lymphomas. Serious and sometimes fatal infections including bacterial, mycobacterial (e.g., tuberculosis), fungal, viral including viral reactivation, and other opportunistic infections have been reported in patients who have received deuruxolitinib. Opportunistic infections include tuberculosis, multidermatomal herpes zoster, oral/esophageal candidiasis, and cryptococcosis. Lymphoma and other malignancies, including non-melanoma skin cancers, have also been observed with the use of deuruxolitinib and other Janus kinase (JAK) inhibitors.

MANAGEMENT: Concomitant use of deuruxolitinib with other Janus kinase (JAK) inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or potent immunosuppressants (e.g., azathioprine, cyclosporine) is not recommended. Patients receiving deuruxolitinib should be closely monitored for the development of signs and symptoms of infection during and after treatment, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. If a patient develops a serious infection, deuruxolitinib therapy should be interrupted until the infection is controlled.